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Abstract
Genome-wide association studies (GWAS) have identified multiple single nucleotide polymorphisms (SNPs) associated with
prostate cancer risk. However, whether these associations can be consistently replicated, vary with disease aggressiveness
(tumor stage and grade) and/or interact with non-genetic potential risk factors or other SNPs is unknown. We therefore
genotyped 39 SNPs from regions identified by several prostate cancer GWAS in 10,501 prostate cancer cases and 10,831
controls from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). We replicated 36 out of 39 SNPs (P-values
ranging from 0.01 to 10228). Two SNPs located near KLK3 associated with PSA levels showed differential association with
Gleason grade (rs2735839, P = 0.0001 and rs266849, P = 0.0004; case-only test), where the alleles associated with decreasing
PSA levels were inversely associated with low-grade (as defined by Gleason grade ,8) tumors but positively associated with
high-grade tumors. No other SNP showed differential associations according to disease stage or grade. We observed no
effect modification by SNP for association with age at diagnosis, family history of prostate cancer, diabetes, BMI, height,
smoking or alcohol intake. Moreover, we found no evidence of pair-wise SNP-SNP interactions. While these SNPs represent
new independent risk factors for prostate cancer, we saw little evidence for effect modification by other SNPs or by the
environmental factors examined.
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Introduction
Prostate cancer is the most common non-skin cancer among
men in industrialized countries, but beyond age, ethnicity and
family history, very little is known about its etiology. Observed
familial aggregation together with evidence from both twin and
epidemiological studies demonstrate a key role for inherited
genetic variants [1].
Genome-wide association studies (GWAS) conducted within the
last few years have identified multiple common single nucleotide
polymorphisms (SNPs) associated with prostate cancer risk [2–15].
However, the function of these SNPs (or the causal variants these
SNPs serve as proxies for) remains largely unknown and data
describing their correlation with clinical factors or their interplay
with other genetic and non-genetic factors are sparse, mainly due
to the large sample sizes needed for sufficient statistical power.
To this end, we selected 39 SNPs from regions identified in
previous GWAS and genotyped them in 10,501 prostate cancer
cases and 10,831 controls within the NCI Breast and Prostate
Cancer Cohort Consortium (BPC3). We tested each SNP for
association with two strongly predictive clinical factors: Gleason
grade and tumor stage. We investigated interactions between
SNPs and known and potential environmental risk factors. Finally,
we performed exploratory analysis to identify possible pair-wise
SNP-SNP interactions.
Results
Association between SNPs and prostate cancer risk
Subject characteristics are displayed in Table 1. All 39 SNPs
were significantly associated with prostate cancer risk (Table 2)
and directions of associations were consistent with previous
findings [2–4,6–8,10,12,14]. Although risk estimates varied
somewhat between different cohorts (Table S1 and Figure S1),
we observed overall no strong statistical evidence for heterogeneity
(P.0.01). Risk effects per allele ranged from 1.06 (rs2928679) to
1.44 (rs16901979). Carriers of two copies of the rare ‘A’ allele of
rs16901979 had a 3-fold increased risk to develop prostate cancer
in this population. The allele frequency of rs16901979 varies
widely across ethnicities (Hapmap population frequencies: 0.03 in
CEU, 0.26 in CHB and 0.58 in YRI), and thus might explain a
part of the differences seen in prostate cancer incidence across
populations. Based on p-value, we observed the strongest
association for rs4430796 located in HNF1B/TCF2 (OR: 0.80
(95% CI: 0.77–0.83), P = 2.09N10228) and the weakest association
for rs4961199 near CPNE3 (OR: 1.07 (95% CI: 1.02–1.14),
P = 0.012). In addition, rs266849 near KLK3 was only weakly
associated with prostate cancer risk (OR: 0.93 (95% CI: 0.89–
0.98), P = 0.009). rs266849 was initially identified in a GWAS
using controls selected for low prostate-specific antigen (PSA) levels
(,0.5 ng/ml) [4] and it has been suggested that rs266849 is a
marker for circulating PSA levels rather than for prostate cancer
risk [16,17].
The primary analysis in most GWAS assumes an additive
increase in risk for each risk allele carried. rs4961199 (P= 0.02)
was the only SNP showing nominally significant evidence of
departure from additivity in our data. This was not unexpected
since rs4961199 was initially identified using a recessive inheri-
tance model [12].
Replication in non-CGEMS cohorts
Eleven of the 39 SNPs included in this paper were identified
through the Cancer Genetic Markers of Susceptibility (CGEMS)
project (http://cgems.cancer.gov/) which has partial overlap with
BPC3. Eight of these eleven SNPs were identified through
CGEMS stage 2 including ATBC, CPS-II, HPFS and PLCO.
We attempted to replicate these SNPs in the other cohorts (EPIC,
MCCS, MEC and PHS) which collectively comprise 4,661
prostate cancer cases and 5,288 controls. Out of these eight SNPs,
six replicated (Table S2) and two did not (rs4961199 near CPNE3
(OR: 0.99 (95% CI: 0.91–1.08), P = 0.82) and rs4962416 in
CTBP2 (OR: 1.01 (95% CI: 0.95–1.08), P = 0.73)). Three SNPs
(rs4857841 (EFFSEC), rs7841060 (8q24) and rs620861 (8q24))
were identified in CGEMS stage 3 (that in addition to ATBC,
CPS-II, HPFS and PLCO included EPIC and MEC). Therefore,
we tested these three SNPs in MCCS and PHS only (2,700 cases
and 2,412 controls). Both rs7841060 (OR: 1.25 (95% CI: 1.12–
1.40), P = 8.8N1025) and rs620861 (OR: 0.89 (95% CI: 0.80–0.98),
P = 0.01) were associated with prostate cancer risk whereas
rs4857841 was not (OR: 1.03 (95% CI: 0.93–1.15), P = 0.52).
Since we did not replicate rs4857841, rs4961199 and rs4962416 in
the non-CGEMS studies, we did not pursue these SNPs in further
analysis
SNP associations by tumor stage and grade
We next examined whether any SNP was differentially
associated with tumor grade or stage at diagnosis (Table 3). A
total of 1,717 cases were classified as high-stage (stage C or D at
diagnosis) and 1,388 were classified as high-grade (Gleason grade
8–10 or equivalent, i.e. coded as poorly differentiated or
undifferentiated). For 15% of the cases, we did not have
information about tumor stage or Gleason grade. The minor
alleles of two SNPs in the KLK3 gene (rs266849 and rs2735839),
which have been previously associated with decreasing PSA levels
[16,17], were inversely associated with low-grade disease (Gleason
,8) (OR: 0.91 (0.86–0.96) for rs266489, OR: 0.84 (0.79–0.89) for
rs2735839) but associated with increased risk for high-grade
disease (OR: 1.10 (1.00–1.22) for rs266489, OR: 1.07 (0.95–1.19)
for rs2735839). The differences in SNP associations between low-
grade and high-grade disease were statistically significant in case-
only analysis (P = 0.0004 for rs266849 and P= 0.0001 for
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Table 2. Associations between selected SNPs and prostate cancer risk.
SNP Pos Chr Gene
N
Cases
N
Controls
MAF
Cases
MAF
Controls OR Het OR Hom OR allele P-value Ref
rs721048 62,985,235 2 EHBP1 10160 10474 0.19 0.18 1.12
(1.06–1.19)
1.22
(1.04–1.42)
1.11
(1.06–1.17)
2.47E-05 1
rs1465618 43,407,453 2 THADA 9758 9627 0.23 0.21 1.09
(1.00–1.19)
1.18
(0.97–1.43)
1.12
(1.06–1.17)
1.02E-05 12
rs12621278 173,019,799 2 ITGA6 9822 9667 0.05 0.06 0.88
(0.76–1.02)
0.32
(0.13–0.83)
0.86
(0.78–0.94)
0.0010 12
rs2660753 87,193,364 3 – 10000 10502 0.12 0.11 1.12
(1.05–1.20)
1.32
(1.05–1.66)
1.13
(1.06–1.20)
9.18E-05 2
rs4857841 129,529,333 3 EEFSEC 9589 10103 0.30 0.28 1.13
(1.07–1.20)
1.28
(1.15–1.42)
1.13
(1.08–1.18)
2.32E-08 3
rs17021918 95,781,900 4 PDLIM5 9791 9702 0.32 0.34 0.88
(0.81–0.96)
0.84
(0.73–0.97)
0.92
(0.88–0.96)
5.35E-05 12
rs12500426 95,733,632 4 PDLIM5 9784 9643 0.48 0.47 1.07
(0.97–1.19)
1.14
(1.02–1.29)
1.07
(1.02–1.11)
0.0021 12
rs7679673 106,280,983 4 TET2 9772 9613 0.39 0.42 0.82
(0.74–0.89)
0.74
(0.65–0.85)
0.88
(0.84–0.92)
6.74E-10 12
rs9364554 160,753,654 6 SLC22A3 9994 10464 0.29 0.28 1.08
(1.02–1.15)
1.15
(1.04–1.27)
1.08
(1.03–1.12)
0.00086 2
rs10486567 27,943,088 7 JAZF1 10242 10618 0.21 0.24 0.82
(0.78–0.87)
0.73
(0.64–0.83)
0.84
(0.80–0.88)
7.05E-14 4
rs6465657 97,654,263 7 LMTK2 9994 10465 0.48 0.46 1.13
(1.06–1.21)
1.23
(1.14–1.33)
1.11
(1.07–1.16)
1.52E-07 2
rs1512268 23,582,408 8 NKX3–1 9849 9732 0.46 0.44 1.12
(1.02–1.23)
1.28
(1.14–1.44)
1.11
(1.06–1.15)
5.52E-07 12
rs2928679 23,494,920 8 SLC25A37 9845 9697 0.46 0.44 1.01
(0.91–1.11)
1.16
(1.03–1.30)
1.06
(1.02–1.11)
0.0036 12
rs4961199 87,650,060 8 CPNE3,CNGB3 9184 9147 0.17 0.16 1.03
(0.97–1.10)
1.36
(1.13–1.64)
1.07
(1.02–1.14)
0.012 4
rs1016343 128,162,479 8 – 9636 10116 0.24 0.20 1.22
(1.15–1.30)
1.64
(1.44–1.88)
1.25
(1.19–1.31)
1.54E-19 2
rs7841060 128,165,659 8 – 9341 9859 0.24 0.20 1.22
(1.15–1.30)
1.63
(1.42–1.86)
1.24
(1.18–1.31)
1.43E-18 3
rs16901979 128,194,098 8 – 9120 9079 0.05 0.03 1.41
(1.26–1.58)
3.02 (1.47–
6.23)
1.44
(1.29–1.60)
1.55E-11 5
rs620861 128,404,855 8 – 9097 9611 0.34 0.37 0.86
(0.81–0.92)
0.75
(0.68–0.82)
0.87
(0.83–0.90)
3.59E-11 3
rs6983267 128,482,487 8 – 10186 10521 0.44 0.49 0.82
(0.77–0.87)
0.66
(0.61–0.71)
0.81
(0.78–0.84)
6.62E-26 4
rs1447295 128,554,220 8 – 9640 10098 0.14 0.10 1.38
(1.29–1.48)
1.94
(1.53–2.47)
1.38
(1.30–1.47)
8.06E-25 6
rs4242382 128,586,755 8 – 10296 10630 0.14 0.10 1.41
(1.31–1.51)
1.95
(1.55–2.47)
1.40
(1.32–1.49)
4.17E-28 4
rs7837688 128,608,542 8 – 9624 10133 0.13 0.10 1.34
(1.25–1.44)
1.96
(1.54–2.50)
1.36
(1.27–1.44)
6.70E-22 7
rs16902094 128,389,528 8 8407 8378 0.18 0.16 1.23
(1.11–1.36)
1.10
(0.81–1.48)
1.18
(1.11–1.25)
4.78E-08 13
rs1571801 123,467,194 9 – 9961 9833 0.27 0.25 1.08
(1.02–1.15)
1.11
(0.99–1.24)
1.07
(1.02–1.12)
0.0049 8
rs10993994 51,219,502 10 MSMB 9982 10493 0.44 0.39 1.20
(1.12–1.27)
1.53
(1.41–1.66)
1.23
(1.18–1.28)
5.95E-25 4
rs4962416 126,686,862 10 CTBP2 10020 10348 0.29 0.27 1.07
(1.01–1.13)
1.23
(1.11–1.37)
1.09
(1.05–1.14)
7.92E-05 4
rs7127900 2190150 11 9793 9694 0.22 0.20 1.20
(1.09–1.31)
1.62
(1.31–2.00)
1.14
(1.09–1.20)
2.01E-07 12
rs12418451 68,691,995 11 – 9641 10129 0.31 0.29 1.12
(1.05–1.19)
1.27
(1.15–1.41)
1.12
(1.08–1.17)
1.42E-07 9
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rs2735839). These results remained significant after Bonferroni
correction (P= 0.014 for rs266849 and P= 0.0036 for rs2735839).
No other SNP was differentially associated with tumor grade or
stage after adjusting for multiple testing.
Association between non-genetic factors and prostate
cancer risk
We tested for association between prostate cancer risk and
potential non-genetic risk factors including family history of
prostate cancer, diabetes, BMI, height, smoking and alcohol
consumption. As expected, we observed a strong association
between family history of prostate cancer and prostate cancer risk
(OR: 1.77, 95% CI: 1.59–1.96, P= 1.88N10227) as well as between
diabetes and prostate cancer risk (OR: 0.73, 95% CI: 0.64–0.83,
P = 1.61N1026). Adjusting for BMI did not alter the association
between diabetes and prostate cancer (data not shown). BMI was
inversely associated with prostate cancer risk (OR: 0.996 (95% CI:
0.994–0.998) per BMI unit increase, P = 0.0004). This association
was limited to obese men (BMI .30) compared to normal weight
men (BMI,25) (OR: 0.86, 95% CI: 0.79–0.94, P= 0.0009), and
we observed no association for being overweight (OR: 0.99, 95%
CI: 0.93–1.05, P= 0.64). Adjusting for diabetes and smoking
attenuated the association between obesity and prostate cancer risk
(OR: 0.89, 95% CI: 0.82–0.98, P= 0.02). The inverse association
between BMI and prostate cancer risk was restricted to non-
aggressive cases as defined by Gleason grade ,8 and tumor stages
A and B (data not shown). Height was not associated with prostate
cancer risk, when analyzed as a continuous variable (OR: 1.001,
95% CI: 1.000–1.002 per cm increase, P= 0.12) or in tertiles (OR:
1.02, 95% CI: 0.99–1.06, P= 0.24). We observed a non-significant
reduced prostate cancer risk among both former smokers (OR:
0.95, 95% CI: 0.89–1.01, P= 0.08) and current smokers (OR:
0.91, 95% CI: 0.82–1.00, P= 0.06) compared to never smokers.
Adjusting for alcohol consumption or BMI did not change the
results (data not shown). Finally, consuming more than 30 g
alcohol per day (corresponding to two drinks) was associated with
an increased prostate cancer risk (OR: 1.09, 95% CI: 1.01–1.18,
P= 0.03). Adjusting for smoking did not alter this association (data
not shown).
SNP-environment and SNP-SNP interactions
To investigate if the associations with family history of prostate
cancer, diabetes and BMI were stronger in specific genetic strata,
we tested for effect modification by including a SNPxE interaction
term in the model. We also tested for SNP effect modification of
age at diagnosis (studying the main effect of age is not appropriate
SNP Pos Chr Gene
N
Cases
N
Controls
MAF
Cases
MAF
Controls OR Het OR Hom OR allele P-value Ref
rs7931342 68,751,073 11 – 9765 10226 0.45 0.49 0.86
(0.81–0.92)
0.71
(0.66–0.77)
0.85
(0.81–0.88)
1.11E-16 2
rs10896449 68,751,243 11 – 10122 10504 0.45 0.50 0.86
(0.80–0.91)
0.70
(0.65–0.76)
0.84
(0.81–0.87)
3.58E-19 4
rs11649743 33,149,092 17 TCF2 10184 10538 0.17 0.19 0.87
(0.82–0.92)
0.76
(0.65–0.89)
0.87
(0.83–0.92)
7.55E-08 10
rs4430796 33,172,153 17 TCF2 9984 9785 0.44 0.49 0.80
(0.75–0.85)
0.64
(0.59–0.69)
0.80
(0.77–0.83)
2.09E-28 11
rs7501939 33,175,269 17 TCF2 9557 10082 0.36 0.40 0.80
(0.76–0.86)
0.69
(0.63–0.75)
0.82
(0.79–0.86)
2.78E-20 2
rs1859962 66,620,348 17 – 10202 10547 0.53 0.48 1.23
(1.15–1.32)
1.41
(1.31–1.53)
1.19
(1.14–1.24)
2.74E-18 11
rs266849 56,040,902 19 KLK3 10015 10348 0.18 0.19 0.91
(0.86–0.97)
0.94
(0.81–1.09)
0.93
(0.89–0.98)
0.0085 2
rs2735839 56,056,435 19 KLK3 9862 10366 0.13 0.15 0.90
(0.84–0.96)
0.67
(0.54–0.82)
0.87
(0.82–0.92)
3.05E-06 2
rs5759167 41,830,156 22 BIK 9843 9729 0.47 0.50 0.83
(0.75–0.91)
0.70
(0.62–0.79)
0.87
(0.83–0.90)
1.30E-12 12
rs5945572 51,246,423 X NUDT11 9338 9830 0.40 0.35 1.22
(1.15–1.29)
6.17E-11 1
rs5945619 51,258,412 X NUDT11 9999 10456 0.41 0.36 1.23
(1.16–1.31)
8.27E-13 2
1.Gudmundsson, et al. 2008.
2.Eeles, et al. 2008.
3.Yeager, et al. 2009.
4.Thomas, et al. 2008.
5.Gudmundsson, et al. 2007.
6.Amundadottir, et al. 2006.
7.Yeager, et al. 2007.
8.Duggan, et al. 2007.
9.Zheng, et al. 2009.
10.Sun, et al. 2009.
11.Gudmundsson, et al. 2007.
12. Eeles et al. 2009
13.Gudmundsson et al 2009
doi:10.1371/journal.pone.0017142.t002
Table 2. Cont.
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since our population comprises of a series of nested case-control
studies matched on age). After adjusting for multiple testing, no
SNP showed significant statistical interaction with any of the non-
genetic factors tested (Table S3 and Table S4). Of note, two SNPs
in the 8q24 region (rs620861, P= 0.05 and rs6983267, P= 0.004)
showed nominally significant interactions with age at diagnosis,
with the association being stronger in younger men. These results
are in line with previous reports of stronger associations with
earlier onset of disease for SNPs in the 8q24 region [6,18,19]. We
observed marginally significant interactions between diabetes and
rs10486567 in JAZF1 (P = 0.04) and between BMI and
rs10486567 (P= 0.03). This is of particular interest since genetic
variation in JAFF1 has been associated with diabetes, albeit not the
same genetic variants. In this study, obesity was associated with a
reduced risk for prostate cancer. It has been shown that BMI is
inversely associated with PSA levels [20] and thus, obese men are
Table 3. Associations between selected SNPs and Gleason grade and Stage.
Odds Ratio1 (95% CI) Odds Ratio1 (95% CI)
SNP Gleason ,8 Gleason 8–10 P case-only test Stage AB StageCD P case-only test
rs721048 1.13 (1.07–1.20) 1.07 (0.96–1.19) 0.30 1.13 (1.07–1.20) 1.09 (0.99–1.19) 0.5
rs1465618 1.10 (1.05–1.16) 1.17 (1.06–1.30) 0.15 1.13 (1.07–1.19) 1.07 (0.97–1.17) 0.34
rs12621278 0.87 (0.79–0.96) 0.77 (0.62–0.95) 0.27 0.87 (0.78–0.96) 0.85 (0.71–1.02) 0.86
rs2660753 1.10 (1.03–1.18) 1.11 (0.98–1.26) 0.81 1.13 (1.05–1.21) 1.14 (1.01–1.27) 0.82
rs4857841 1.13 (1.07–1.18) 1.15 (1.05–1.26) 0.54 1.14 (1.09–1.20) 1.15 (1.06–1.25) 0.53
rs17021918 0.91 (0.87–0.95) 0.96 (0.88–1.05) 0.22 0.89 (0.58–0.93) 1.01 (0.93–1.09) 0.004
rs12500426 1.07 (1.03–1.12) 0.99 (0.91–1.08) 0.09 1.08 (1.04–1.13) 0.97 (0.89–1.04) 0.007
rs7679673 0.88 (0.84–0.92) 0.86 (0.79–0.94) 0.63 0.88 (0.84–0.92) 0.85 (0.78–0.92) 0.49
rs9364554 1.10 (1.05–1.15) 1.03 (0.94–1.13) 0.28 1.07 (1.02–1.12) 1.13 (1.04–1.22) 0.30
rs10486567 0.83 (0.78–0.88) 0.93 (0.83–1.05) 0.06 0.81 (0.77–0.85) 0.91 (0.84–1.00) 0.02
rs6465657 1.10 (1.05–1.15) 1.09 (1.01–1.18) 0.80 1.12 (1.07–1.17) 1.03 (0.96–1.11) 0.02
rs1512268 1.11 (1.06–1.16) 1.02 (0.94–1.11) 0.08 1.12 (1.07–1.17) 1.05 (0.97–1.13) 0.05
rs2928679 1.07 (1.03–1.12) 1.09 (1.00–1.19) 0.81 1.08 (1.03–1.12) 1.05 (0.97–1.14) 0.78
rs4961199 1.10 (1.04–1.17) 1.08 (0.97–1.22) 0.82 1.08 (1.01–1.15) 1.10 (0.99–1.22) 0.70
rs1016343 1.24 (1.17–1.31) 1.31 (1.18–1.45) 0.33 1.26 (1.19–1.33) 1.25 (1.15–1.37) 0.92
rs7841060 1.23 (1.17–1.30) 1.31 (1.18–1.45) 0.32 1.26 (1.19–1.33) 1.24 (1.13–1.36) 0.82
rs16901979 1.43 (1.27–1.60) 1.39 (1.12–1.72) 0.91 1.40 (1.24–1.58) 1.55 (1.29–1.86) 0.33
rs620861 0.85 (0.81–0.89) 0.89 (0.81–0.97) 0.34 0.87 (0.83–0.91) 0.82 (0.75–0.89) 0.37
rs6983267 0.80 (0.77–0.84) 0.84 (0.77–0.91) 0.62 0.82 (0.78–0.85) 0.82 (0.76–0.89) 0.54
rs1447295 1.41 (1.32–1.51) 1.31 (1.16–1.49) 0.35 1.36 (1.27–1.46) 1.51 (1.36–1.68) 0.06
rs4242382 1.43 (1.34–1.53) 1.38 (1.22–1.55) 0.73 1.39 (1.30–1.49) 1.49 (1.34–1.66) 0.24
rs7837688 1.39 (1.30–1.49) 1.33 (1.18–1.51) 0.72 1.34 (1.25–1.44) 1.47 (1.32–1.64) 0.09
rs16902094 1.19 (1.12–1.27) 1.07 (0.94–1.21) 0.08 1.18 (1.10–1.26) 1.18 (1.06–1.31) 0.74
rs1571801 1.07 (1.02–1.13) 1.10 (1.01–1.21) 0.50 1.07 (1.02–1.13) 1.09 (1.00–1.19) 0.62
rs10993994 1.23 (1.18–1.29) 1.21 (1.12–1.32) 0.94 1.25 (1.19–1.30) 1.20 (1.11–1.29) 0.29
rs4962416 1.10 (1.05–1.16) 1.09 (1.00–1.20) 0.93 1.10 (1.05–1.15) 1.10 (1.01–1.19) 0.88
rs7127900 1.14 (1.08–1.21) 1.05 (0.95–1.17) 0.14 1.14 (1.08–1.20) 1.16 (1.06–1.28) 0.81
rs12418451 1.11 (1.06–1.17) 1.20 (1.10–1.31) 0.09 1.14 (1.08–1.19) 1.06 (0.97–1.15) 0.14
rs7931342 0.86 (0.82–0.90) 0.81 (0.75–0.88) 0.21 0.85 (0.81–0.89) 0.88 (0.81–0.94) 0.33
rs10896449 0.85 (0.82–0.89) 0.80 (0.74–0.87) 0.13 0.84 (0.80–0.87) 0.86 (0.80–0.93) 0.34
rs11649743 0.88 (0.83–0.93) 0.93 (0.84–1.03) 0.40 0.89 (0.84–0.94) 0.84 (0.76–0.93) 0.21
rs4430796 0.78 (0.75–0.81) 0.84 (0.77–0.91) 0.05 0.81 (0.77–0.84) 0.78 (0.73–0.85) 0.47
rs7501939 0.81 (0.77–0.85) 0.85 (0.77–0.92) 0.30 0.83 (0.80–0.87) 0.80 (0.74–0.86) 0.28
rs1859962 1.20 (1.15–1.25) 1.17 (1.08–1.27) 0.70 1.18 (1.13–1.24) 1.22 (1.13–1.31) 0.58
rs266849 0.91 (0.86–0.96) 1.10 (1.00–1.22) 0.0004 0.92 (0.87–0.97) 0.98 (0.89–1.08) 0.18
rs2735839 0.84 (0.79–0.89) 1.07 (0.95–1.19) 0.0001 0.85 (0.80–0.91) 0.92 (0.83–1.03) 0.17
rs5759167 0.87 (0.83–0.91) 0.85 (0.78–0.93) 0.59 0.88 (0.84–0.92) 0.82 (0.76–0.89) 0.11
rs5945572 1.24 (1.16–1.32) 1.20 (1.06–1.36) 0.56 1.22 (1.14–1.31) 1.27 (1.14–1.42) 0.57
rs5945619 1.26 (1.19–1.34) 1.19 (1.05–1.34) 0.26 1.22 (1.14–1.30) 1.33 (1.20–1.28) 0.16
1Odds ratios were estimated using multinomial regression.
doi:10.1371/journal.pone.0017142.t003
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less likely to get diagnosed through PSA screening. Because BMI
was associated with non-aggressive disease, we also looked at
possible SNP-BMI interactions stratified by disease aggressiveness
but observed no significant interactions (data not shown).
To assess if the ambiguous associations between prostate cancer
risk and height, smoking and alcohol consumption are due to
hidden SNP-environment interactions, we conducted a joint test of
the environmental main effect and the SNP-environment
interaction effect. This test has proven powerful when the non-
genetic effect is limited to a specific genetic stratum [21]. Across
SNPs, the joint test was not significant for either alcohol or
smoking after adjustment for multiple testing (Table S5, Table S6
and Table S7). Similarly, standard interaction tests between SNPs
and height, SNPs and smoking and SNPs and alcohol consump-
tion were not significant. Exploratory analyses of all possible pair-
wise SNP-SNP interactions revealed no excess in significant
interactions than expected by chance (50 out of 630 tests, Table
S8). Furthermore, no SNP-SNP interaction was significant after
correcting for multiple testing using a Bonferroni correction
(lowest nominal P-value was 0.0005). Yeager and colleagues
identified a SNP-SNP interaction between rs4242382 and
rs620861 (P = 0.002) [13]. We also observe this interaction
(P = 0.02), but not when the analysis was restricted to only MCCS
and PHS (P= 0.75).
Discussion
In this study, we set out to examine whether SNPs identified in
GWAS to be associated with prostate cancer show variation in risk
by disease aggressiveness (tumor stage and grade) and/or interact
with non-genetic and genetic factors. All 39 SNPs tested were
significantly associated with prostate cancer in the overall analysis.
However, the CGEMS project, which included four and six BPC3
studies in its second and third stage stages, respectively,
contributed to identification of eleven SNPs investigated in the
present study. We tested whether associations for these eleven
SNPs could be confirmed in the remaining studies and with the
exception of three SNPs, the findings were replicated with risk
magnitudes similar to those in the CGEMS analysis. We could not
replicate rs4961149 using data from three of the non-CGEMS
cohorts. Since rs4961199 was included in CGEMS stage 2 based
on its recessive association, we also tested the recessive model in
the non-CGEMS studies and observed a non-significant associa-
tion similar but weaker as compared with CGEMS (OR: 1.10,
95% CI: 0.82–1.47, P= 0.54).
Few of the observed associations differed by disease stage, tumor
grade or environmental exposures. The most noteworthy finding
was the qualitatively altered association according to Gleason
grade for two SNPs near KLK3 (rs266849 and rs2735839), where
the minor alleles were associated with lower risk of low-grade
disease but higher risk of Gleason 8–10 tumors. This was
previously observed by Kader and colleagues [22] who studied
5,000 patients and found a strong association between Gleason
grade and rs2735839 (P= 3.7N1027). The minor alleles of these
SNPs have been associated with lower PSA levels indicating that
carriers are less likely to be diagnosed at an early stage through
PSA screening [16,17]. However, we did not observe any
difference in the association of these two SNPs by disease stage,
suggesting that delayed diagnosis might not fully explain these
associations. Interestingly, the significant positive association of
these two SNPs with Gleason 8–10 tumors support the clinical
observations that PSA expression is lower in malignant than in
normal prostatic epithelium and is further reduced in poorly
differentiated tumors [23,24]. Together, these results suggest that
KLK variation might influence high-grade prostate cancer risk
through a yet unidentified pathway or simply as a genetic marker
of the probability of a diagnosis of high versus low-grade prostate
cancer diagnosis through its influence on PSA levels. To test this
hypothesis, we performed case-only analysis based on year of
diagnosis to reflect the introduction of wide-spread PSA screening
(up to 1992 (670 men) vs. after 1992 (9831 men)). If the association
between Gleason grade and KLK3 variation is due to altered PSA
levels, we would expect to see differential associations according to
year of diagnosis. We did not observe such differences, however,
suggesting that the KLK3-prostate cancer association is not
mediated by altered PSA levels. A recent Icelandic study
conducted stratified analysis based on year of diagnosis and
noticed that the association with prostate cancer was confined to
the group of cases diagnosed in 1992 or later. These results suggest
that the association between the KLK3 locus and prostate cancer
is driven by the increasing frequency of PSA testing [25].
After adjusting for multiple testing, no other SNP was associated
with clinical sub-types. Earlier studies had failed to link these SNPs
to clinical characteristics [22,26], suggesting that these SNPs affect
prostate cancer risk overall and not solely for more (or less)
aggressive or advanced cancer.
We found overall no evidence that these SNPs interact with
known or proposed risk factors for prostate cancer including family
history of prostate cancer risk, age of onset, diabetes, BMI, height,
smoking or alcohol consumption. Studying the interactions
between SNPs and diabetes was of particular interest since genetic
variation in JAZF1 and TCF2 has been associated with both
prostate cancer and diabetes [8,11,12,27,28]. We did see a
borderline statistically significant interaction between rs10486567
in JAZF1 and diabetes, but this particular SNP has not been
associated with diabetes risk. A previous study conducted in CPS-
II and PLCO found that diabetes did not mediate the association
between JAZF1 and HNF1B/TCF2 SNPs and prostate cancer risk
[29], and we observed no statistical interaction between diabetes
and three SNPs in HNFIB/TCF2.
We observed no significant associations between prostate cancer
risk and smoking or height and only a weak association between
prostate cancer and alcohol consumption, even after accounting
for the possibility of differences in the effects of these exposures by
genotype. A meta-analysis of 39 studies observed that height was
positively associated with risk (RR 1.05 per 10 cm increment, 95%
CI 1.02–1.09) but the association was only seen in cohort studies
[30]. A recent large meta-analysis of smoking and prostate cancer
incidence found overall no evidence of an association but reported
an increased risk when considering number of cigarettes smoked.
Moreover, they observed a 9% risk increase for former smokers
[31]. We did observe a marginal association between alcohol
intake and prostate cancer risk. This is in line with earlier results
indicating a weak risk increase for men consuming at least 25
grams alcohol per day (OR: 1.05 (95% CI: 1.00–1.08)) and for
men consuming at least 50 grams per day (OR: 1.09 (95% CI:
1.02–1.17)) [32].
Overall, these results imply that the lack of robust associations
between these environmental factors and prostate cancer risk is not
due to interactions between these exposures and variation in any
of the 36 SNPs assessed in this study. However, the lack of
significant interactions does not rule out that gene-environment
interactions exist in prostate cancer. All SNPs under study have
been linked to prostate cancer through their main effects. Agnostic
approaches such as incorporating gene-environment interactions
in a genome-wide association study setting might identify genetic
variants that only affect risk when acting with other factors. The
lack of significant interactions can also reflect the low power to
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detect only modest interaction effects despite our sample size of
10,000 cases and 10,000 controls. It is important to note that our
results do not rule out small departures from a multiplicative odds
model for the joint effect of pairs of individual markers and risk
factors, nor does absence of departure from a multiplicative odds
model necessarily imply that these genetic loci and risk factors do
not interact in some causal manner. Moreover, absence of
interaction as defined here does not imply absence of a ‘‘public
health interaction’’, where the benefit from reducing a risk factor
in terms of absolute risk reduction differs across genotypes [33].
This is, to our knowledge, the first large-scale study to explore
possible interactions between confirmed prostate cancer suscepti-
bility markers and a broad spectrum of known and possible
environmental factors. The SNPs considered in this study show
marginal per-allele odds ratios ranging between 1.07 and 1.44. It is
possible that these odds ratios might be larger in strata defined by
other prostate cancer risk factors, not evaluated in this study. It is
well recognized that exploring such interactions requires large
study populations with well-defined exposure data. With 10,501
prostate cancer cases, 10,831 controls and prospectively collected
data within established cohorts, BPC3 is in a unique position to
explore both gene-gene and gene-environment interactions as
demonstrated here. For example, in the absence of main effects
(which is not the same as assuming no marginal effect and
plausibly consistent with modest marginal genetic or environmen-
tal effects), the BPC3 has 89% power to detect an interaction effect
of 1.2 assuming an allele frequency of 20% and an environmental
exposure with a prevalence of 20%.
As with all studies utilizing environmental exposure data, the
present investigation would be expected to have some degree of
misclassification in the measurement of those factors. It is possible
that alternative modeling of the environmental risk factors or more
precise exposure quantification would increase statistical power
(e.g. analyzing intensity, duration or pack-years of smoking rather
than as never/former/current). However, a critical issue in
conducting pooled analysis across studies is to harmonize data.
As exposure data gets more refined, there is an increasing risk of
discrepancies between cohorts which increases the risk of
‘‘misclassification’’. Since our study cohorts (MEC exempted)
included predominantly men of European ancestry, we were
limited in our ability to study other ethnicities.
Genome-wide association studies have been particularly suc-
cessful for prostate cancer. Recently published secondary analysis
of GWAS has now added ,10 additional prostate cancer SNPs to
those presented here [5,9,11]. At time of this study, we did not
have genotype data for these SNPs in BPC3 and it remains to be
seen if they are differentially associated with clinical subtypes or if
they interact with non-genetic factors.
In summary, we independently replicated the association
between prostate cancer risk and 36 SNPs identified in multi-
stage genome-wide association studies of prostate cancer. Except
for SNPs in KLK3 that were differentially associated with Gleason
grade, we did not detect any differentiation in SNP associations
according to Gleason grade or stage at diagnosis, two clinical
factors strongly predictive of disease outcome. Moreover, we found
no strong evidence that these SNPs interact with age, family
history, diabetes, BMI, height, smoking or alcohol consumption.
Materials and Methods
Study Population
The BPC3 has been described in detail elsewhere [34]. In brief,
the consortium combines resources from seven well-established
cohort studies with blood samples collected as follows: the Alpha-
Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study in
1992-1993 [35], American Cancer Society Cancer Prevention
Study II (CPS-II) in 1998 [36], the European Prospective
Investigation into Cancer and Nutrition Cohort (EPIC –
comprised of cohorts from Denmark, Great Britain, Germany,
Greece, Italy, the Netherlands, Spain, and Sweden) in 1993 [37],
the Health Professionals Follow-up Study (HPFS) in 1993 [38], the
Multi-Ethnic Cohort (MEC) in 1995 [39], the Physicians’ Health
Study (PHS) in 1982 [40], and the Prostate, Lung, Colorectal, and
Ovarian (PLCO) Cancer Screening Trial in 1993–2001 [41]. In
addition, the Melbourne Collaborative Cohort Study (MCCS)
established in 1990–1994 [42] recently joined the consortium.
Together, these eight cohorts collectively include over 265,000
men who provided a blood sample.
Prostate cancer cases were identified through population-based
cancer registries or self-reports confirmed by medical records,
including pathology reports. Except for the MCCS study, the
BPC3 consists of a series of matched nested case-control studies
within each cohort; controls were matched to cases on a number of
potential confounding factors, such as age, ethnicity, and region of
recruitment, depending on the cohort. MCCS used a case-cohort
design, with a randomly sampled sub-cohort serving as controls.
Written informed consent was obtained from all subjects and each
study was approved by the Institutional Review Boards at their
respective institutions. The IRBs for each study were as follows:
US National Cancer Institute and National Institute for Health
and Welfare (Helsinki, Finland) (ATBC), The Emory University
School of Medicine Institutional Review Board (CPS-II), Ethik-
kommission - Medizinische Fakulta¨t Heidelberg and Imperial
College Research Ethics Committee (EPIC), The Institutional
Review Board of Harvard School of Public Health (HPFS), The
Cancer Council Victoria Human Research Ethics Committee
(MCCS), The Institutional Review Board at the University of
Southern California and the Institutional Review Board at the
University of Hawaii (MEC), The Human Subjects Committee at
Brigham and Women’s Hospital (PHS) and NCI Special Studies
Institutional Review Board (PLCO).
The current study was restricted to individuals who self-reported
as being Caucasian. We had genotype data for a total of 10,501
prostate cancer cases and 10,831 controls. Data on disease stage
and grade at time of diagnosis were collected from each cohort,
wherever possible. A total of 1,717 cases were classified as high-
stage (stage C or D at diagnosis) and 1,388 were classified as high-
grade (Gleason grade .7 or equivalent, i.e. coded as poorly
differentiated or undifferentiated). For 15% of the cases, we did
not have information about tumor stage or Gleason grade.
Baseline information of height and body weight, family history
of prostate cancer, cigarette smoking status (never, past, and
current), alcohol intake (g/day) and information about a pre-
existing diabetes diagnosis were collected by self-report. Family
history, which was defined as having at least one first-degree family
member diagnosed with prostate cancer, was available for all but
two cohort studies (PHS and EPIC). For some countries in EPIC,
weight and height was measured.
Collection and harmonization of non-genetic data
We collected data on family history, diabetes at baseline,
smoking, alcohol consumption, height and BMI for each study.
Family history of prostate cancer was dichotomized into ‘‘yes’’
(1,780 subjects) or ‘‘no’’ (12,382 subjects). Age was calculated at
age of diagnosis/selection as control except for MCCS (at baseline
for controls) and MEC (at blood draw for controls) and further
dichotomized into younger or equal to 65 years old or older than
65 years. BMI was calculated based on baseline weight (kg) and
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height (m) categorized into 3 categories: normal weight
(BMI,25 kg/m2, 7,947 subjects), overweight (BMI 25–30 kg/
m2, 10,206 subjects) and obese (BMI.30 kg/m2, 2,771 subjects).
Height was analyzed both as a continuous variable and in tertiles
(,173 cm (7,221 subjects), 173–180 cm (7,324 subjects) and
.180 cm (6,548 subjects).
Smoking was categorized into 3 categories: never (7,725
subjects), former (9,457 subjects) and current (3,989 subjects).
Alcohol was dichotomized into never and moderate drinkers
(,30 g/day or two drinks per day; 17,398 subjects) or heavy
drinkers ($30 g/day or 2 drinks per day; 3,257 subjects). Pre-
existing diabetes was dichotomized into ‘‘yes’’ (982 subjects) or
‘‘no’’ (19,643 subjects).
We agreed on a common protocol prior to data collection based
on data availability in the studies. Each study was responsible for
sending the data in a format as described in the protocol to
facilitate data harmonization. We agreed on collecting as detailed
information as possible without having to exclude any study due to
lack of covariate information (that is, we aimed for the least
common denominator for the variables of interest). Inconsistencies
or clarifications were handled by a dialogue between the data
coordinating center and the individual studies. All studies have
published analysis on these variables earlier and details on quality
checks can be found in study-specific publications. All statistical
analyses were conducted centrally.
SNP selection and genotyping
We selected 39 SNPs based on the literature for prostate cancer
GWAS (Table 2). These include (genomic location in parenthesis):
rs721048 (2p15), rs1465618 (2p21), rs12621278 (2q31.3), rs2660753
(3q12.1), rs4857841 (3q21.3), rs17021918 (4q22.3), rs12500426
(4q22.3), rs7679673 (4q24), rs9364554 (6q25.3), rs10486567
(7p15.2), rs6465657 (7p21.3), rs1512268 (8p21.2), rs2928679
(8p21.2), rs4961199 (8q21.3), rs1016343 (8q24.21), rs7841060
(8q24.21), rs16901979 (8q24.21), rs620861 (8q24.21), rs6983267
(8q24.21), rs1447295 (8q24.21), rs4242382 (8q24.21), rs7837688
(8q24.21), rs16902094 (8q24.21), rs1571801 (9p33.2), rs10993994
(10q11.23), rs4962416 (10q26.13), rs7127900 (11p15.5), rs12418451
(11q13.2), rs7931342 (11q13.2), rs10896449 (11q13.2), rs11649743
(17q12), rs4430796 (17q12), rs7501939 (17q12), rs1859962 (17q24.3),
rs266849 (19p13.33), rs2735839 (19p13.33), rs5759167 (22q13.2),
rs5945572 (Xp11.22) and rs5945619 (Xp11.22). For rs12418451, we
used genotypes from either rs12418451 or rs10896438 (r2= 0.964 in
HapMap CEU population) and for and rs2928679 we used
genotypes from either and rs2928679 or rs13264338 (r2=0.966 in
HapMap CEU population). We did not have genotype data on
rs4961199, rs16901979 and rs16902094 for MCCS.
Genotyping was performed using the TaqMan assay (Applied
Biosystems, Foster City, CA) in five different genotyping
laboratories: Core Genotyping Facility at National Cancer
Institute, Harvard School of Public Health, University of South
California, DKFZ and UK Cancer Research. Blinded duplicated
samples indicated no genotyping error. For each autosomal SNP,
we tested HWE in the controls in each study separately. All
autosomal SNPs were in HWE (P.0.01).
Statistical methods
We tested the association between prostate cancer risk and each
SNP with a likelihood ratio test based on unconditional logistic
regression. We adjusted all analyses for study and age at diagnosis
or selection as a control in five year intervals using indicator
variables. All odds ratios are calculated per copy of the minor
alleles (0,1,2) carried. For each SNP, we used Cochran’s Q statistic
to test for heterogeneity between studies.
To estimate odds ratios for high-grade or low-grade disease, we
performed multinomial regression with an outcome variable coded
as 0 (control), 1 (low-grade) or 2 (high-grade). To test for
differential SNP associations between low-grade and high-grade
disease, we used a likelihood ratio test based on case-only analysis.
We repeated this analysis for high-stage/low-stage disease.
We tested for interaction between SNPs and non-genetic factors
by conducting a one degree-of-freedom likelihood ratio test of a
single interaction term (SNPxE) as implemented in an uncondi-
tional logistic regression. When an environmental factor had more
than two categories (as is the case for smoking, BMI and height),
we used ordinal coding for the interaction term. To explore
whether associations with proposed environmental risk factors
may have been masked by effect heterogeneity, we performed a
joint (2 d.f.) test of the environmental main effect and the
interaction effect. This test has been shown to outperform the
standard marginal test when the environmental effect is restricted
to a genetic stratum [21]. Cohorts with no variability in exposure
(such as ATBC and smoking) were excluded from gene-
environment interaction analyses. We tested for pair-wise SNP-
SNP interactions using a one degree-of-freedom likelihood ratio
test of a single interaction term as described for the SNP-
environment interaction tests.
We tested for dominance deviation from an additive model by
including an additional SNP covariate coded as (0,1,0) for
(homozygote common allele, heterozygote, homozygote rare
allele) respectively. Based on unconditional regression, we
performed a one degree-of-freedom likelihood ratio test where
the full model was tested against a model only including the SNP
covariate with additive coding (0,1,2) as described above. All
reported P values are two-sided and uncorrected for multiple
hypothesis testing. Analyses were conducted in R [43] and SAS
version 9.1.
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